Table 1. Antiproliferative activity of ST7612AA1 on different human tumor cell lines.

Tumor cell line	IC50 (μM)
Ovarian cancer A2780 SKOV-3	0.043±0.01 0.38±0.003
Breast cancer MDA-MB436 MDA-MB231 MCF-7	0.18±0.01 0.23±0.009 0.19±0.02
NSCLC NCI-H460 NCI-H1975	0.066±0.01 0.50±0.05
Colon cancer HCT116	0.075±0.01
Acute myeloid leukemia MV4;11 U937	0.19±0.02 0.049±0.005
T-cell lymphoma HUT78	0.48±0.02
Chronic myeloid leukemia K562	0.19±0.02
Diffuse large B-cell lymphoma of the germinal center B-cell type DOHH2 OCI-Ly8 OCI-Ly7 SUDHL-6 SUDHL-4 VAL Karpas422	0.046±0.01 0.24±0.01 0.56±0.02 0.63±0.02 0.98±0.01 2.36±0.1 2.66±0.2
Diffuse large B-cell lymphoma of the activated B-cell like type TMD8 OCI-Ly10 U2932	0.10±0.03 0.26±0.01 0.80±0.02
Splenic marginal zone lymphoma K1718 VL51 SSK41	0.10±0.01 0.12±0.09 0.26±0.05
Mantle cell lymphoma Jeko-1 MAVER1 Granta-519 REC-1	0.25±0.01 0.39±0.02 0.47±0.05 0.55±0.02

Tumor cells were treated for 72 h at different concentrations to evaluate IC₅₀ values. IC₅₀ values were determined using ALLFIT program, a sigmoidal dose response model. Results are the means ± S.E.M. of three independent experiments.